UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): November 6, 2018
Creative Medical Technology Holdings, Inc.
(Exact name of registrant as specified in its charter)
| Nevada | 000-53500 | 87-0622284 | ||
|
(State or other jurisdiction of incorporation) |
(Commission File Number) |
(I.R.S. Employer Identification No.) |
| 2017 W Peoria Avenue, Phoenix, AZ 85029 |
| (Address of principal executive offices) |
Registrant’s telephone number, including area code: (833) 336-7636
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| ¨ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| ¨ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| ¨ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ¨ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company x
Emerging growth company If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨
| Item 8.01 | Other Events |
On November 6, 2018, Creative Medical Technology Holdings, Inc., a Nevada corporation (the “Company”), issued a press release announcing a new design to its Caverstem™ website.
The press release, furnished as Exhibit 99.1 to this Form 8-K, may contain forward-looking statements. Such forward-looking statements are based on information presently available to the Company’s management and are current only as of the date made. Actual results could also differ materially from those anticipated as a result of a number of factors, including, but not limited to, those discussed in the Company’s Annual Report on Form 10-K for the year ended December 31, 2017, and subsequent reports filed by the Company with the Securities and Exchange Commission (the “Commission”). For those reasons, undue reliance should not be placed on any forward-looking statement. The Company assumes no duty or obligation to update or revise any forward-looking statement, although it may do so from time to time as management believes is warranted or as may be required by applicable securities law. Any such updates or revisions may be made by the registrant by filing reports with the Commission, through the issuance of press releases or by other methods of public disclosure.
| Item 9.01. | Financial Statements and Exhibits |
(d) Exhibits.
| Exhibit No. | Description | |
| 99.1 | Press Release dated November 6, 2018 |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| Creative Medical Technology Holdings, Inc. | ||
| Date: November 6, 2018 | By: | /s/ Timothy Warbington |
| Timothy Warbington, Chief Executive Officer | ||
Exhibit 99.1
Creative Medical Technology Holdings, Inc. Announces New Design To Caverstem Website Including New Features For Physician/Patient Engagement
PHOENIX, Nov. 6, 2018 /PRNewswire/ -- Creative Medical Technology Holdings, Inc. (OTCQB ticker symbol CELZ) announced today that as a continuation of the Brand Building of its CaverStemTM technology, it has awarded a contract to PatientGain Medical Marketing for the new design of its CaverStemTM website and to provide online strategy with a focus on acquiring and engagement of new patients for physicians offering the CaverStem™ procedure.
"Upon evaluating different medical marketing platforms and reviewing PatientGain's technology and deep healthcare industry knowledge, we determined that their system that covers healthcare CRM, medical website creation for conversion, Search Engine Marketing, HIPAA Compliant Facebook Apps, Texting/SMS marketing, Email Marketing, content creation and enterprise level support fit our needs," said Timothy Warbington, CEO of Creative Medical Technology Holdings, Inc.
"We are appreciative and honored that a company like Creative Medical Technology Holdings is using PatientGain's Medical Marketing platform for CaverStem™ marketing across online channels including Web, Social Media, Email and Texting/SMS with HIPAA compliance. Our technology for healthcare marketing is being used by medical professionals in the USA and Canada and we are excited to be part of the CaverStemTM expansion," said Sal Khan, CEO of PatientGain.
PatientGain's data shows that out of a sample of 3450 Medical Clinics in USA, only 4.3 percent clinics have a results driven online patient acquisition and engagement marketing plan.
"In addition to gaining much greater online exposure for the CaverStemTM brand, by utilizing this technology CaverStemTM will interface with each physician's office to facilitate real time responses to patient inquiries and questions. As the CaverStemTM network grows we will be able to scale and maintain our efficiency in communicating with physician's and patient's, scheduling physician consultations and follow up appointments, all conducted under HIPAA compliance," Mr. Warbington further said.
Physician's in several cities are currently being trained on the use of the PatientGain platform and the newly designed Caverstem.com website is expected to launch within the next 10 days.
Please visit CaverStem.com to view our website and follow us on Facebook, Twitter, Instagram and You Tube.
About Creative Medical Technology Holdings
Creative Medical Technology Holdings, Inc. is a clinical stage biotechnology company currently trading on the OTCQB under the ticker symbol CELZ. For further information about the company go to www.creativemedicaltechnology.com. For more information on our CaverStemTM procedure please go to www.caverstem.com.
Forward-Looking Statements
OTC Markets has not reviewed and does not accept responsibility for the adequacy or accuracy of this release. This news release may contain forward-looking statements including but not limited to comments regarding the timing and content of upcoming clinical trials and laboratory results, marketing efforts, funding, etc. Forward-looking statements address future events and conditions and, therefore, involve inherent risks and uncertainties. Actual results may differ materially from those currently anticipated in such statements. See the periodic and other reports filed by Creative Medical Technology Holdings, Inc. with the Securities and Exchange Commission and available on the Commission's website at www.sec.gov.